Comparison of accelerated hypofractionation and stereotactic body radiotherapy for Stage 1 and node negative Stage 2 non-small cell lung cancer (NSCLC)

Lung Cancer

Volumn 85, Issue 1, 2014, Pages 59-65

  Lucas, John T ^a   Kuremsky, Jeffrey G ^a   Soike, Mike ^a   Hinson, William W ^a   Kearns, William T ^a   Hampton, Carnell J ^a   Blackstock, A William ^a   Urbanic, James ^a  

^a WAKE FOREST BAPTIST HEALTH   (United States)

Author keywords

Accelerated hypofractionated radiotherapy; Involved field radiotherapy; Lung cancer; Non small cell lung cancer; Radiation; Stereotactic body radiation therapy

Indexed keywords

ANTINEOPLASTIC AGENT;

ADENOCARCINOMA; AFRICAN AMERICAN; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CHRONIC PAIN; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; HUMAN; LUNG FUNCTION TEST; LUNG INSUFFICIENCY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIOTHERAPY UNIT; RETROSPECTIVE STUDY; RIB FRACTURE; SALVAGE THERAPY; SQUAMOUS CELL CARCINOMA; STEREOTACTIC BODY RADIATION THERAPY; SURGICAL RISK; THORAX PAIN; THORAX WALL; TOXICITY; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RADIOSURGERY; TREATMENT OUTCOME;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; DOSE FRACTIONATION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RADIOSURGERY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84901606122     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.04.003     Document Type: Article

References (22)

1. Baumann P., Nyman J., Lax I. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage i lung cancer. A retrospective analysis of patients treated in the Nordic countries. Acta Oncol 2006, 45:787-795.
2. Benedict S.H., Yenice K.M., Followill D. Stereotactic body radiation therapy: the report of AAPM task group 101. Med Phys 2010, 37:4078-4101.
3. Bogart J.A., Hodgson L., Seagren S.L. Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904. J Clin Oncol 2010, 28:202-206.
4. Bradley J. A randomized phase iii comparison of standard-dose (60Gy) versus high-dose (74Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small cell lung cancer: results on radiation dose in RTOG 0617. 2013 ASCO Annual Meeting 2013, 31.
5. Bradley J., Graham M.V., Winter K. Toxicity and outcome results of RTOG 9311: A phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 2005, 61:318-328.
6. Bradley J., Thorstad W.L., Mutic S. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004, 59:78-86.
7. Chang J.Y., Balter P.A., Dong L. Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2008, 72:967-971.
8. Cheung P., Faria S., Ahmed S. A phase II study of accelerated hypofractionated 3-dimensional conformal radiation therapy for inoperable T1-3 no mo non-small cell lung cancer: NCIC CTG BR.25. Int J Radiat Oncol Biol Phys 2012, 84:S47-S48.
9. Emami B., Lyman J., Brown A. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991, 21:109-122.
10. Grills I.S., Mangona V.S., Welsh R. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol 2010, 28:928-935.
11. Marks L.B., Bentzen S.M., Deasy J.O. Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys 2010, 76:S70-S76.
12. Nagata Y., Hiraoka M., Mizowaki T. Survey of stereotactic body radiation therapy in Japan by the Japan 3-D conformal external beam radiotherapy group. Int J Radiat Oncol Biol Phys 2009, 75:343-347.
13. Onishi H., Shirato H., Nagata Y. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007, 2:S94-S100.
14. Timmerman R.D., Paulus R., Pass H.I., Gore E., Edelman M.J., Galvin J.M., et al. RTOG 0618: stereotactic body radiation therapy (SBRT) to treat operable early-stage lung cancer patients. 2013 ASCO Annual Meeting Proceedings 2013, 31.
15. Sibley G.S., Jamieson T.A., Marks L.B. Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the duke experience. Int J Radiat Oncol Biol Phys 1998, 40:149-154.
16. Soliman H., Cheung P., Yeung L. Accelerated hypofractionated radiotherapy for early-stage non-small-cell lung cancer: long-term results. Int J Radiat Oncol Biol Phys 2011, 79:459-465.
17. Takeda A., Sanuki N., Kunieda E. Stereotactic body radiotherapy for primary lung cancer at a dose of 50Gy total in five fractions to the periphery of the planning target volume calculated using a superposition algorithm. Int J Radiat Oncol Biol Phys 2009, 73:442-448.
18. Timmerman R., McGarry R., Yiannoutsos C. Excessive toxicity when treating central tumors in a phase ii study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006, 24:4833-4839.
19. Timmerman R., Paulus R., Galvin J. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010, 303:1070-1076.
20. Timmerman R.D. An overview of hypofractionation and introduction to this issue of seminars in radiation oncology. Semin Radiat Oncol 2008, 18:215-222.
21. Urbanic J.J., Turrisi A.T., Sharma A.K. Conformal high dose external radiation therapy, 80.5Gy, alone for medically inoperable non-small cell lung cancer: a retrospective analysis. J Thorac Oncol 2006, 1:112-119.
22. Yung T., Giuliani M.E., Le L.W. Outcomes of accelerated hypofractionated radiotherapy in stage I non-small-cell lung cancer. Curr Oncol 2012, 19:e264-e269.